BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party - Summary - MDSpire

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

  • By

  • Raffaella Greco

  • Riccardo Saccardi

  • Marta Ponzano

  • Manuela Badoglio

  • Grzegorz Helbig

  • Marek Smilowski

  • Alice Mariottini

  • Joachim Burman

  • Kristina Carlson

  • Majid Kazmi

  • Paolo A. Muraro

  • Ian Gabriel

  • Barbara Withers

  • Jennifer Massey

  • Riccardo Varaldo

  • Matilde Inglese

  • Jaime Sanz

  • Sara Gil-Perotin

  • Basil Sharrack

  • Elisa Roldan

  • Chiara Nozzoli

  • Alessio Signori

  • Maria Pia Sormani

  • Tobias Alexander

  • John A. Snowden

  • September 29, 2025

  • 0 min

Share

Objective:

To compare the effectiveness, safety, and tolerability of BEAM/ATG and CYC/ATG conditioning regimens in MS patients undergoing autologous HSCT, highlighting the importance of this comparison in treatment strategies.

Key Findings:
  • NEDA at 5 years was 81% for BEAM/ATG (CI: 68-96%) and 71% for CYC/ATG (CI: 63-80%) (p = 0.29).
  • Severe adverse events and prolonged hospitalization were more common with BEAM/ATG.
  • No larger studies or prospective trials directly comparing these regimens exist.
Interpretation:

Both conditioning regimens show similar efficacy in achieving NEDA, but BEAM/ATG may have higher associated risks, which could influence treatment decisions.

Limitations:
  • Retrospective nature may introduce bias.
  • Data reported voluntarily by centers may affect completeness and accuracy, potentially skewing results.
Conclusion:

Further prospective studies are needed to validate findings and better understand the safety and efficacy of BEAM/ATG versus CYC/ATG in MS patients, particularly focusing on long-term outcomes.

Original Source(s)

BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

  • by Raffaella Greco, Riccardo Saccardi, Marta Ponzano, Manuela Badoglio, Grzegorz Helbig, Marek Smilowski, Alice Mariottini, Joachim Burman, Kristina Carlson, Majid Kazmi, Paolo A. Muraro, Ian Gabriel, Barbara Withers, Jennifer Massey, Riccardo Varaldo, Matilde Inglese, Jaime Sanz, Sara Gil-Perotin, Basil Sharrack, Elisa Roldan, Chiara Nozzoli, Alessio Signori, Maria Pia Sormani, Tobias Alexander, John A. Snowden

  • September 29, 2025

Related Content

CAR T cells and T cell engagers for autoimmunity—lessons from hematology

OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)

Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis